Sympathetic Ablation for Ventricular Arrhythmias

ConditionVentricular Tachycardia (VT)

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorSymKardia

About this trial

Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 or older at the time of informed consent

Willing and capable of providing written informed consent

Implanted ICD or CRT-D

Recurrent VT leading to ICD therapy (ATP or shock)

Disqualifiers

Contraindication to percutaneous femoral arterial access

Heparin-induced thrombotic thrombocytopenia

Prior surgical sympathectomy

ECMO therapy in the past 30 days

Trial design

Design model

Single group

Treatments tested in this trial

Central sympathetic nerve ablation
Device
Catheter-based ablation of an extra-cardiac nerve target

Treatment groups

10 Participants

are divided into 1 treatment group

Group A: TherapyExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

Freedom from device and procedure-related serious adverse events (SAEs)

Time frame

3 months

VT burden (episodes per month)

VT burden post-ablation will be compared to VT burden pre-ablation

Time frame

3 months

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

SymKardia

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: